title: To evaluate efficacy and safety of Caralluma fimbriata in overweight and obese patients: A randomized, single blinded, placebo control trial.
abstract: OBJECTIVE
  The aim of the following study is to evaluate the efficacy and safety of Caralluma fimbriata extract (CFE) in overweight and obese individuals in a prospective, randomized, placebo controlled trial.
  
  
  METHODS
  Commercially available CFE was assessed in overweight and obese individuals. A total of 89 patients were randomized into a treatment group (n = 47) and placebo group (n = 42) to receive either CFE in the form capsules/oral 500 mg b.d. for 12 weeks or matching placebo in similar way. Patients were evaluated clinically and biochemically at 4, 8 and 12 weeks for anthropometric measurements, appetite, biochemical investigations and other safety parameters.
  
  
  RESULTS
  At the end of study period both CFE and placebo for 12 weeks caused only numerical reduction in weight, body mass index, waist circumference, hip circumference and waist hip ratio in overweight and obese individuals. However, these parameters failed to attain significant statistical levels (P ≥ 0.05). CFE and placebo both failed to elucidate any modification of the appetite. There were no significant changes in the biochemical and clinical parameters in both the test and placebo group. However, CFE was well-tolerated and adverse events noted were mild and transient in nature.
  
  
  CONCLUSIONS
  A commercially available extract of CFE in an oral dose of 1 g/day claimed to have anti-obesity effect failed to yield any positive results on anthropometry and appetite in overweight and obese individuals beyond placebo. There were also no significant differences in the clinical and biochemical parameters. However, CFE was well tolerated. Thereby, underscoring the need to carry more research before CFE is recommended as an anti-obesity drug.
authors: Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Ekta
authors: E
authors: Arora
authors: Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Vijay
authors: V
authors: Khajuria
authors: Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Vishal R
authors: VR
authors: Tandon
authors: Department of Internal Medicine, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Atul
authors: A
authors: Sharma
authors: Department of Internal Medicine, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Annil
authors: A
authors: Mahajan
authors: Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Zahid H
authors: ZH
authors: Gillani
authors: Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.
authors: Naiyma
authors: N
authors: Choudhary
keywords: Anti-obesity drugs; Caralluma fimbriata; appetite; herbal; obesity
references: Lancet. 2005 Apr 16-22;365(9468):1389-97
references: 15836887
references: BMJ. 2010 Feb 09;340:c824
references: 20144986
references: Int J Obes Relat Metab Disord. 2003 Dec;27(12):1437-46
references: 12975638
references: JAMA. 2002 Nov 6;288(17):2176
references: 12413382
references: Obes Rev. 2005 May;6(2):93-111
references: 15836459
references: Circulation. 2002 Dec 17;106(25):3143-421
references: 12485966
references: Int J Obes Relat Metab Disord. 1992 Jun;16(6):397-415
references: 1322866
references: Arch Intern Med. 1999 Oct 11;159(18):2177-83
references: 10527295
references: World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
references: 11234459
references: Arch Intern Med. 2002 Sep 9;162(16):1867-72
references: 12196085
references: N Engl J Med. 1997 Aug 28;337(9):581-8
references: 9271479
references: JAMA. 2006 Feb 15;295(7):761-75
references: 16478899
references: Indian J Exp Biol. 2007 Nov;45(11):929-36
references: 18072536
references: Int J Obes Relat Metab Disord. 2002 Feb;26(2):262-73
references: 11850760
references: Appetite. 2007 May;48(3):338-44
references: 17097761
references: Obes Res. 2000 May;8(3):270-8
references: 10832771
references: Pharmacol Rep. 2009 Mar-Apr;61(2):217-24
references: 19443932